Analysis of the immune response to Fendrix as compared to double-dose Engerix B in HIV-infected non-responders to standard Hepatitis B vaccination courses

Trial Profile

Analysis of the immune response to Fendrix as compared to double-dose Engerix B in HIV-infected non-responders to standard Hepatitis B vaccination courses

Recruiting
Phase of Trial: Phase II

Latest Information Update: 08 Feb 2017

At a glance

  • Drugs Hepatitis B vaccine recombinant (Primary)
  • Indications Hepatitis B
  • Focus Pharmacodynamics
  • Most Recent Events

    • 08 Feb 2017 Last checked against European Clinical Trials Database record.
    • 08 Feb 2017 Planned number of patients changed from 30 to 10.
    • 25 Oct 2015 Accrual to date is 3% according to United Kingdom Clinical Research Network record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top